Public Market Listing
3692 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (17 total) 17 Total Assets
1 Approved
10 Phase 3 / Filed
6 Phase 1–2 / Early
16 Diseases
Disease: All diseases (17) Psoriasis (3) Chronic Kidney Disease (3) Non-Small Cell Lung Cancer (2) Schizophrenia (2) Type 2 Diabetes (2) Systemic Lupus Erythematosus (1) Myasthenia Gravis (1) Psoriatic Arthritis (1) Obesity (1) Hidradenitis Suppurativa (1) Small Cell Lung Cancer (1) Esophageal Cancer (1) Chronic Hepatitis B (1) Major Depressive Disorder (1) Atherosclerotic Cardiovascular Disease (1) Hypertension (1)
Stage: All stages (17) Approved / Phase 4 (1) Phase 3 / Filed (10) Phase 2 Phase 1 / Preclinical
Quick filter: All (17) Psoriasis (3) Chronic Kidney Disease (3) Non-Small Cell Lung Cancer (2) Schizophrenia (2) Type 2 Diabetes (2)
Showing 17 of 17 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved CD19 Monoclonal antibody
Systemic Lupus Erythematosus Myasthenia Gravis
Generalized Myasthenia Gravis Phase 3 EGFR Small molecule
Non-Small Cell Lung Cancer
Phase 3 TYK2 Small molecule
Psoriatic Arthritis Psoriasis
Phase 3 Dopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target) Small molecule
Phase 3 IL-23 p19 Monoclonal antibody
Phase 3 GLP-1/GIP receptor (dual) Peptide
Obesity Type 2 Diabetes Hidradenitis Suppurativa
Phase 3 GLP-1 receptor Peptide
Phase 3 Erythropoietin receptor (EPO-R) Peptide
Phase 3 B7-H3 Antibody–drug conjugate
Non-Small Cell Lung Cancer Small Cell Lung Cancer Esophageal Cancer
Esophageal Squamous Cell Carcinoma Phase 3 Calcium-sensing receptor (CaSR) Small molecule
Phase 3 HBV polymerase (reverse transcriptase) Small molecule
Phase 2 GABA-A receptor Small molecule
Major Depressive Disorder
Phase 2 Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) Small molecule
Phase 2 IL-23 receptor Peptide
Phase 1 Undisclosed / early pipeline Small molecule
Show all 17 assets (2 more) ↓ Upcoming events (26 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (10) February 2027 (1) HS-20118 Phase 2 Moderate to Severe Plaque Psoriasis Est. primary completion 2027-02-28 ·
NCT07765628 ·
CT.gov ↗ What to watch
March 2027 (4) HS-20137 Phase 2 Moderate-to-severe Plaque Psoriasis Est. primary completion 2027-03-01 ·
NCT07879885 ·
CT.gov ↗ What to watch
olatorepatide Phase 3 Type 2 Diabetes Est. primary completion 2027-03-30 ·
NCT07156500 ·
CT.gov ↗ What to watch
olatorepatide Phase 3 Type 2 Diabetes Est. primary completion 2027-03-30 ·
NCT07156539 ·
CT.gov ↗ What to watch
HS-20137 Phase 3 Moderate-to-severe Plaque Psoriasis Est. primary completion 2027-03-31 ·
NCT06844799 ·
CT.gov ↗ What to watch
April 2027 (1) Inebilizumab Phase 2 Neuromyelitis Optica Spectrum Disorder Est. primary completion 2027-04-13 ·
NCT05549258 ·
CT.gov ↗ What to watch
November 2027 (4) Est. primary completion 2027-11-05 ·
NCT07602777 ·
CT.gov ↗ What to watch
HS-10390 Phase 2 Chronic Kidney Disease Est. primary completion 2027-11-11 ·
NCT07555054 ·
CT.gov ↗ What to watch
2028 (7) January 2028 (1) olatorepatide Phase 2 Overweight or Obesity Est. primary completion 2028-01-21 ·
NCT07685808 ·
CT.gov ↗ What to watch
March 2028 (1) July 2028 (1) HS-10380 Phase 3 SCHIZOPHRENIA 1 (Disorder) Est. primary completion 2028-07-31 ·
NCT07759869 ·
CT.gov ↗ What to watch
August 2028 (1) Inebilizumab Phase 2 Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis Est. primary completion 2028-08-06 ·
NCT06570798 ·
CT.gov ↗ What to watch
November 2028 (1) olatorepatide Phase 2 Hidradenitis Suppurativa Est. primary completion 2028-11-24 ·
NCT07830329 ·
CT.gov ↗ What to watch
December 2028 (2) olatorepatide Phase 3 Overweight or Obesity Without Diabetes Est. primary completion 2028-12-19 ·
NCT07896265 ·
CT.gov ↗ What to watch
2029 (4) January 2029 (2) HS-10380 Phase 3 SCHIZOPHRENIA 1 (Disorder) Est. primary completion 2029-01-24 ·
NCT07911787 ·
CT.gov ↗ What to watch
June 2029 (1) December 2029 (1) 2030 (2) March 2030 (1) Inebilizumab Phase 2 Generalized Myasthenia Gravis Est. primary completion 2030-03-13 ·
NCT06987539 ·
CT.gov ↗ What to watch
December 2030 (1) Risvutatug rezetecan Phase 3 Esophageal Squamous Cell Carcinoma (ESCC) Est. primary completion 2030-12-31 ·
NCT07621601 ·
CT.gov ↗ What to watch
2031 (3) June 2031 (1) Inebilizumab Phase 2 Immunoglobulin G4-related Disease Est. primary completion 2031-06-10 ·
NCT07222553 ·
CT.gov ↗ What to watch
July 2031 (1) Inebilizumab Phase 3 Autoimmune Hepatitis, AIH Est. primary completion 2031-07-30 ·
NCT07598825 ·
CT.gov ↗ What to watch
September 2031 (1) Inebilizumab Phase 3 Glomerulonephritis, Membranous Est. primary completion 2031-09-27 ·
NCT07851220 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (12) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
21 September 2026 Topline result HS-10374 Pivotal Phase 3 of HS-10374 in plaque psoriasis meets both co-primary endpoints 2 September 2026 Filing accepted Risvutatug rezetecan China's NMPA accepts the BLA for HS-20093 (risvutatug rezetecan) in small cell lung cancer CN, NMPA · Hansoh Pharmaceutical Group ·
Source ↗ 9 June 2026 Filing accepted SHR6508 NMPA accepts the NDA for HS-10568 (SHR6508) in secondary hyperparathyroidism of CKD on hemodialysis China, NMPA · Hansoh Pharmaceutical Group Company Limited ·
Source ↗ June 2026 Filing accepted olatorepatide NMPA accepts olatorepatide NDA 9 March 2026 Topline result olatorepatide Positive Phase 3 topline results for olatorepatide in Chinese adults with obesity 7 March 2026 Topline result olatorepatide Phase 3 study of olatorepatide (HS-20094) in China met its co-primary endpoints at week 48 12 February 2026 Approval Inebilizumab European Commission approves UPLIZNA for generalized myasthenia gravis 11 December 2025 Approval Inebilizumab FDA approves UPLIZNA for generalized myasthenia gravis 3 April 2025 Approval Inebilizumab FDA approves UPLIZNA for IgG4-RD 15 October 2024 Topline result Inebilizumab MINT Phase 3 primary results 5 June 2024 Topline result Inebilizumab MITIGATE (NCT04540497) Phase 3 met its primary endpoint Financial reports Quarterly & interim (1)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-H1 $1.0B $199M $3.8B — report ↗
Hansoh Pharmaceutical Group reported revenue of $1,025.71M, R&D spend of $198.81M, and cash and equivalents of $3,783.79M for H1 2025.
Figures only: this period's report disclosed no narrative text
Annual history (6 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $2.1B $468M $4.5B — report ↗
View 5 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $1.7B $376M $3.1B — report ↗ 2023-FY $1.4B $297M $3.2B — report ↗ 2022-FY $1.4B $252M $2.5B — report ↗ 2021-FY $1.5B $279M $2.3B — report ↗ 2020-FY $1.3B $182M $657M — report ↗